Fig. 2From: Effect of growth hormone therapy on liver enzyme and other cardiometabolic risk factors in boys with obesity and nonalcoholic fatty liver diseaseAfter 6 months, change in BMI SDS, IGF-1, CRP, lgALT, AST, lgGGT, lgHDL-C and LDL-C in rhGH treatment group compared with untreated control group. * p < 0.05 vs control groupBack to article page